Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Taxes: 2010-2025

Historic Change in Taxes for Myriad Genetics (MYGN) over the last 13 years, with Sep 2025 value amounting to -$500,000.

  • Myriad Genetics' Change in Taxes rose 61.54% to -$500,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 million, marking a year-over-year decrease of 542.86%. This contributed to the annual value of -$500,000 for FY2024, which is 28.57% up from last year.
  • Latest data reveals that Myriad Genetics reported Change in Taxes of -$500,000 as of Q3 2025, which was up 76.19% from -$2.1 million recorded in Q1 2025.
  • Myriad Genetics' Change in Taxes' 5-year high stood at $18.1 million during Q4 2021, with a 5-year trough of -$90.3 million in Q1 2021.
  • Moreover, its 3-year median value for Change in Taxes was -$500,000 (2025), whereas its average is -$475,000.
  • The largest annual percentage gain for Myriad Genetics' Change in Taxes in the last 5 years was 102.02% (2021), contrasted with its biggest fall of 13,000.00% (2021).
  • Over the past 5 years, Myriad Genetics' Change in Taxes (Quarterly) stood at $18.1 million in 2021, then slumped by 101.10% to -$200,000 in 2022, then crashed by 150.00% to -$500,000 in 2023, then declined by 20.00% to -$600,000 in 2024, then skyrocketed by 61.54% to -$500,000 in 2025.
  • Its Change in Taxes was -$500,000 in Q3 2025, compared to -$2.1 million in Q1 2025 and -$600,000 in Q4 2024.